Complete Heart Block Secondary to Flecainide Toxicity: Is It Time for CYP2D6 Genotype Testing?

doi:10.1542/peds.2019-2608

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Complete Heart Block Secondary to Flecainide Toxicity: Is It Time for CYP2D6 Genotype Testing?

Pediatrics - 1 Jul 2020

Poh Bao Hui, Lee Jan Hau, Abdul Haium Abdul Alim, Choo Tze Liang Jonathan

Abstract excerpt

Flecainide acetate is a Vaughan-Williams class IC antiarrhythmic drug prescribed for the treatment of supraventricular arrhythmias. It has a narrow therapeutic index and proarrhythmic effects even at therapeutic doses. Flecainide is metabolized by a CYP2D6 enzyme that exhibits polymorphism. In this case report, we present, to our best knowledge, the first case of toxicity contributed by genetic polymorphism in an...

Topics

Cytochrome P-450 CYP2D6
Electrocardiography
Flecainide
Genotype
Heart Block
Humans
Infant, Newborn
Polymorphism, Genetic
Tachycardia, Supraventricular
Voltage-Gated Sodium Channel Blockers

Source

Open in PubMed

Identifiers

PMID: 32561613
DOI: 10.1542/peds.2019-2608

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics